Difference between revisions of "DZI20-210-Case-1"

From MGH Learn Pathology
(Automatic edit to upgrade to new templates)
(Updating subject, access, and performer)
Line 12: Line 12:
 
IHC: Aypical lymphocytes are CD3+ CD7+ CD5+ (subset), CD8+, TIA+, Perforin+, Granzyme+, and negative for CD2, CD56, CD4, CD30. CD25 shows weak reactivity in ~40-50% of cells. Mib1 is approximately 90%.
 
IHC: Aypical lymphocytes are CD3+ CD7+ CD5+ (subset), CD8+, TIA+, Perforin+, Granzyme+, and negative for CD2, CD56, CD4, CD30. CD25 shows weak reactivity in ~40-50% of cells. Mib1 is approximately 90%.
 
|reasonCode=70 yo with 3 week history of hemorrhagic tumors
 
|reasonCode=70 yo with 3 week history of hemorrhagic tumors
|subject=public
+
|subject=MGH
|performer=Vn048
+
|performer=VN048
 
|authoredOn=October 21, 2020 02:16:00 PM
 
|authoredOn=October 21, 2020 02:16:00 PM
 
|requester=Vn048
 
|requester=Vn048
 
|sequence=1
 
|sequence=1
 +
|access=public
 
}}
 
}}
 
{{Media
 
{{Media

Revision as of 15:17, June 21, 2022

DZI20-210-Case-1
70 yo with 3 week history of hemorrhagic tumors
SKIN: LEFT upper back and arm: CD8+ cutaneous T cell lymphoma. IHC: Aypical lymphocytes are CD3+ CD7+ CD5+ (subset), CD8+, TIA+, Perforin+, Granzyme+, and negative for CD2, CD56, CD4, CD30. CD25 shows weak reactivity in ~40-50% of cells. Mib1 is approximately 90%.
December 31, 1969 7:00:00 PM